Clinical Trials Browser

Phase 2 × Ketoconazole × Other hematologic neoplasm × Clear all

NCT05638763 2022-12-06

Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia

Phase 2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase